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ABSTRACT 
 
Although Eating Disorders (ED) are known to affect bone health and development, little is 
known about the longitudinal effect of ED and ED behaviours on bone health in community 
dwelling adult women.  
 
Women (n=3,507) enrolled in the Avon Longitudinal Study of Parents and Children 
(ALSPAC) participated in a two-phase prevalence study to assess lifetime ED and ED 
behaviours (fasting, restrictive eating, vomiting and misuse of medication). Crude and adjusted 
linear regression methods investigated the association between ED diagnoses and behaviours, 
and total body, hip, leg and arm bone mineral density (BMD) DXA scans at mean ages of 48 
and 52 years.  
 
Lifetime occurrence of Anorexia Nervosa (AN) was associated with lower BMD Z-scores for 
the whole body (mean difference (MD) =-0.28; 95% CI: -0.49, -0.05), hip (MD=-0.45; 95% CI 
-0.74, -0.16), leg (MD=-0.28; 95% CI -0.52, -0.03) and arm (MD=-0.44; 95% CI -0.68, -0.19) 
compared to no ED. This effect was mostly accounted for by lowest ever BMI. In post-hoc 
analyses, Restrictive AN, but not Binge-Purge AN was associated with a lower total body BMD 
Z-scores (MD=-0.37; 95% CI -0.62, -0.12). Lifetime Fasting and Restrictive Eating were 
associated with low BMD of the total body, hip, arm and leg in adjusted analyses, all p<0.05. 
  
Both lifetime ED diagnoses and ED behaviours in a large community sample were predictive 
of low BMD in mid-life. This study confirms that the effects of AN, fasting and restrictive 
eating, and low BMI on bone health seen in clinical samples also occur in community samples.   
 
Keywords: Eating Disorders, Anorecia Nervosa, Bulimia Nervosa, Osteoporosis, Bone 
Mineral Density, ALSPAC, Women 
 
 
 
 
  
Introduction 
 
Eating Disorders (ED) are severe psychiatric disorders associated with disturbed eating 
behaviours including excessive food restriction, consumption of large quantities of food with 
loss of control, and compensatory behaviours aimed at weight loss; as well as distorted body 
image [1]. ED, particularly Anorexia Nervosa (AN), can lead to several medical complications, 
including low bone mineral density (BMD), bone mineral content (BMC) and bone area (BA) 
[2-4]. Both adults [5, 6] and adolescents [7-9] with an ED, and particularly those with AN, are 
at increased risk for low BMD and BA, and fractures in comparison to healthy women [10]. 
Studies to date have almost exclusively investigated clinical samples to identify the effects of 
ED on bone health and outcomes. As the majority of individuals in the community may never 
receive either a diagnosis or treatment for an ED, population-based studies can shed light on 
the consequences of ED and related behaviours and their burden on individuals across the 
population [11]. 
 
The vast majority of studies investigating bone outcomes in EDs have focused on AN, with a 
recent meta-analysis uncovering only six studies comparing BMD in individuals with Bulimia 
Nervosa (BN) to healthy control women [12]. Research to date investigating bone health in 
AN has revealed that approximately 85% of women with AN have BMD 1 standard deviation 
(SD) below the population mean [2], with approximately 30% of women with a history of AN 
reporting a fracture at one or more anatomical sites over their lifetime [13]. Moreover, the onset 
of AN during adolescence can impair the acquisition of peak bone mass, resulting in lower 
BMD throughout adult life [6] and may limit increases in BMD following recovery [14]. A 
long-term follow-up study of women recovered from AN found that full clinical recovery did 
not always result in normalization of BMD [15]. Similarly, recovery from AN during 
adolescence did not lead to bone parameters comparable to healthy controls [16]. A previous 
population-based retrospective study investigating fracture outcomes in EDs found that the 
cumulative incidence of any fracture at 40 years after the diagnosis of anorexia nervosa was 
57%. Fractures of the hip, spine, and forearm were late complications, occurring on average 
38, 25, and 24 years after diagnosis, respectively  [17].  
 
Previous research on the effect of BN on bone health has utilized either mixed ED samples, or 
samples with a high proportion of individuals with a history of AN, resulting in ambiguous 
findings regarding the impact of BN on BMD [18-20]. A meta-analysis investigating the 
Standardised Mean Difference (SMD) in spinal BMD between women with BN and healthy 
women revealed that women with BN were  30-50% more likely to endure a fracture than 
healthy women [12], warranting further study into bone health parameters in this group. Given 
the evidence that not only AN, but also BN is associated with deficits in BMD [12, 21], it is 
timely to investigate the effect of these EDs on long term BMD. However it remains to be 
determined which ED behaviours might be more strongly related to low BMD in adulthood.  
 
The current study aims to investigate the long-term effects of lifetime AN and BN diagnoses 
on BMD at various bone sites in mid-life. It also aims to determine the long-term effects of 
individual ED behaviours, including fasting, restrictive eating, self-induced vomiting and 
misuse of laxatives/diuretics, on BMD in mid-life in women from a population sample from a 
a prospective study. This is the first study to investigate the effect of EDs and individual ED 
behaviours on bone health parameters using a population-based sample. 
 
Methods 
 
Sample 
The Avon Longitudinal Study of Children and Parents (ALSPAC) is a longitudinal cohort 
study of women and their offspring recruited from South West England by Bristol University 
[22]. ALSPAC recruited 14,541 pregnant women resident in Avon, UK, with expected dates 
of delivery between 1st April 1991 and 31st December 1992. Of these initial pregnancies, there 
were 14,062 live births, and 13,988 children were alive at 1 year of age with 13,761 women 
were included in long-term follow-up. Women and their children have been followed over the 
last 22-24 years; mothers have completed up to 20 questionnaires, and have had detailed data 
abstracted from their medical records [23, 24]. The study website contains details of all 
available data through a fully searchable data dictionary 
(http://www.bris.ac.uk/alspac/researchers/data-access/data-dictionary/). Figure 1 shows a flow 
diagram of recruitment and attrition in the ALSPAC mothers sample.  
 
Between 2009 and 2012 a total of 9,233 women who were still alive, enrolled in the study and 
participating in assessment waves, and were the primary carers for their ALSPAC child, were 
enrolled in a sub-study focusing on EDs (for details about study procedures see Micali et al, 
2017 [25]). Amongst 5,655 respondents who completed a validated questionnaire (Eating 
Disorders Diagnostic Schedule adapted to cover the whole lifespan) [16], 1,524 women were 
selected for interview using the ED section of the Structured Clinical Interview for DSM-IV-
TR disorders (SCID-I) (with no skip rules) [17], supplemented with a version of the LIFE 
interview [18], adapted to EDs [19], aimed at investigating presence, frequency, and duration 
of ED behaviours (restriction, fasting, excessive exercise, binge eating, and purging). Each ED 
behaviour was recorded over the lifetime from its first occurrence to the time of the interview, 
with both frequency and duration recorded. For details about this two-phase study see 
reference.   
 
Outcomes: Bone Health 
Two face-to-face assessment clinics were conducted between 2009 and 2013: Focus on 
Mothers 1 (FOM1), and Focus on Mothers 2 (FOM2).  
 
Women who were still enrolled in ALSPAC were invited to the FOM1 assessment. As shown 
in Figure 1, 4,834 (43% of invited)  attended, at a mean age of 49 (SD =4.5) years. A subset of 
these women who were pre-menopausal or peri-menopausal at the time of FOM1 were invited 
to attend the FOM2 study clinic, with n=2,595 attending (86.5% of those invited)  assessment 
at a mean age of 51 (SD= 4.4) years.  
 
Participants  underwent a DXA Scan using a Lunar Prodigy DXA scanner (GE Medical 
Systems Lunar, Madison, WI, USA) which provided measures of BMD, BMC, BA and also 
fat mass and lean mass, among other measures. Each scan was manually screened for 
anomalies, motion, and material artefacts. Total body, total leg and total arm DXA measures 
were collected in both FOM1 and FOM2 assessments. In addition,  hip DXA measures were 
collected in FOM2 [26]. As total body, leg and arm DXA measurements were highly correlated 
between FOM1 and FOM2 and larger number of women were included in FOM1, we assessed 
total body, total leg and total arm DXA measures at FOM1 and only hip DXA measurements 
from the FOM2 assessment.  
 
Total body BMD and BA were our primary outcome measures, indicating bone density and 
size respectively. Secondary outcomes were hip BMD and BA, leg BMD and BA, and arm 
BMD and BA. Spinal BMD measures were not investigated in this study due to the lack of 
availability of clean data for the spine at the time of data analysis.  
 
Figure 1: Participant Recruitment and Attrition in the ALSPAC Study 
 
 
 
Exposures: 
ED diagnoses 
Lifetime diagnoses of DSM-5 AN and BN were obtained using DSM-5 criteria [26]. 
ED diagnoses and ED behaviours were not investigated as mutually exclusive categories.  
 
 Of 5,320 women included in this study, 59 received a lifetime diagnosis of AN and 55 received 
a BN diagnosis. Of the women who received a diagnosis of AN, 35 were of the Restricting AN 
subtype (AN-R) and 31 were of the binge-purge AN subtype (AN-BP). Women who 
participated in the ED sub-study and screened negative acted as controls (n = 4,708).  
 
Information regarding presence and frequency of lifetime ED behaviours was obtained from 
the SCID and the LIFE interview. Restrictive eating, fasting, vomiting and misuse of 
medication were coded as binary variables and defined as follows:  
 
Restrictive Eating: women who had, at any time in their life, engaged in dietary restriction to 
lose weight or to avoid gaining weight, at a frequency of at least one whole day of severe 
dietary restriction a week for at least 3 months. 
 
Fasting: women who had, at any time in their life, engaged in fasting behaviours including 
skipping meals to lose weight or avoid gaining weight, at a frequency of missing a minimum 
of three meals a week for a period of at least 3 months.  
 
Self-induced Vomiting: women who had, at any time in their life, engaged in self-induced 
vomiting with the aim of losing weight or avoiding gaining weight at a frequency of at least 
once a week for a period of at least 3 months.  
 
Misuse of medication: women who had, at any time in their life, misused medication, including 
the abuse of laxatives, diuretics, or slimming pills, with the aim of losing weight or avoiding 
gaining weight.  
 
Among this sample, 132 women engaged in fasting behaviours, 54 women reported restricting 
food intake, 74 women reported self-induced vomiting and 74 women reported misuse of 
medication in order to control their shape or weight.  
 
Anthropometry 
 
Height, and current weight were obtained objectively contemporaneous to the DXA 
assessments at the ALSPAC base at both FOM1 and FOM2 study clincs; BMI was derived as 
height (cm) / (weight (kg)2). Information regarding the lowest ever reported BMI was obtained 
by questionnaire as part of the ED sub-study. Anthropomorphic measures for AN (AN-R and 
AN-BP, BN and healthy control participants are presented in Table 2 (FOM1 measures) and 
Table 3 (FOM2 measures).  
 
Socio-demographic data 
 
Age was obtained at the FOM1 and FOM2 visits. Women’s ethnicity and educational status 
were obtained by combining data provided at various time-points between enrollment and child 
age 18 years. [25] 
 
Statistical analyses 
Primary Analyses  
Multivariable linear regression models were used to assess the effect of either ED diagnoses or 
ED behaviours on DXA measures of BMD and BA. All models were initially run unadjusted 
and then adjusted for covariates in three steps. Covariates were defined as a priori confounders, 
including maternal age, education, and ethnicity; with a second set of analyses additionally 
including height2 (used as a measure of current body size), and BA in the case of BMD 
analyses, in order to control for current bone size. Height2 was chosen as a measure of current 
body size because BMI is strongly associated with ED diagnoses and behaviours. The effect of 
lowest ever BMI as a mediator on outcomes was investigated by including it into multivariable 
analyses as a third step.  
 
Post-hoc analyses  
Due to the overlap across ED diagnostic categories and behavioural groups, post hoc analyses 
were run with mutually exclusive categories for ED diagnoses and ED behaviours to 
investigate each diagnostic or behavioural group in isolation. All models were initially run 
unadjusted and then adjusted for covariates in the three steps described above.  
Statistical methods  
All analyses used sampling weights (generated from the ED substudy sampling strategy) [27]. 
The sampling weight provides an indication of the ratio of Phase 1 to Phase 2 participants, and 
thus how many Phase 1 participants each Phase 2 participant represents. All analyses were 
performed in Stata (version 13) [28]. The SVYSET command was used in Stata 13 to carry out 
regression analyses allowing for stratified sampling techniques and providing a robust 
estimation of 95% confidence intervals (CI).  All statistical tests presented are two sided, with 
p<0.05 used to define statistical significance.  
 
Attrition and Missing Data 
The final sample for this study included N=5,028 women, who had participated in both Phase 
1 of this study (with a sub-set also participating in Phase 2), and had also attended at least one 
of the FOM1 or FOM2 ALSPAC clinics. Attrition and drop-out from the study were predicted 
by sociodemographic factors: specifically parity (multiparous), and education (>A level) 
significantly predicted attrition. 
 
Data on  BMD and BA measures from the FOM1 clinic were less likely to be missing in those 
with a diagnosis of BN or reporting Fasting (BN: odds ratio [OR]=0.45; Fasting: OR: 0.56). 
Missing data on Hip BMD and BA at the FOM2 clinic were negatively predicted by a BN 
diagnosis and Fasting and Restricting ED behaviours (BN: OR: 0.48; Fasting: OR: 0.72; 
Restricting: OR: 0.54; all p<0.05).  
 
Multiple imputation was used to deal with missing covariate data. All predictor and outcome 
variables were used as predictors in the imputation model, which was set for 10 imputations. 
Analyses were run on complete case and imputed datasets, and a comparison of results showed 
that differences were negligible. Only results based on imputed datasets are presented here as 
complete case analysis is thought to suffer from more chance variation, and multiple random 
imputation is assumed to correct any bias. The rules of Rubin et al. [29] were used to combine 
the estimates to obtain valid overall estimates.  
Ethical Approval 
Ethical approval for this study was granted by the ALSPAC Law and Ethics Committee and 
Local Ethics Committees.  
 
 
Results 
Descriptive Characteristics 
The descriptive characteristics of all participants attending FOM1 and FOM2 clinics are 
described in Table 1. A comparison of descriptive characteristics in ED and non-ED 
participants in the FOM1 and FOM2 ALSPAC study clinics is presented in Table 2 and Table 
3. Current BMI and lowest ever BMI were both lower in women who had received a lifetime 
diagnosis of AN (AN-R or AN-BP) compared to non-ED women, however women with a 
lifetime diagnosis of BN had a comparable current and lowest ever BMI to control women.  
 
Table 1: Whole sample participant characteristics in the ALSPAC FOM1 and FOM2 
assessments 
 
 FOM1   FOM2   
 N Mean SD N Mean  SD 
Age (years) 4,717 48 4.48 2,771 50.82     4.41 
Height (cm) 4,699 164.01 6.13 2762 164.14  6.24 
Weight (kg) 4,696 71.7 14.88 2763 70.92     14.26 
Fat Mass (kg) 4550 27.19     10.95 2,716 27.03 10.91 
Lean Mass (kg) 4550 41.28     5.16 1,829 40.51 5.21 
TBLH BMC (g) 4,550 2167.63 366.18 2716     2612.82    420.39 
TBLH BA (cm2) 4,550 1976.15 232.26 2716     2161.77     240.15 
TBLH BMD (g/cm2) 4,550 1.091 0.08 2716 1.21     0.08 
 
TBLH = Total Body Less Head; BMC = Bone Mineral Content; BMD = Bone Mineral Density; BA = Bone Area  
 
 
Table 2: Participant characteristics (mean (SD)) in ED groups versus Healthy Controls from 
the ALSPAC FOM1 assessment   
 
 
 
AN 
 
BN 
 
HC 
 
 
AN-R 
 
 
AN-BP 
 
    
 N= 36 N=31 N= 54 N= 3006 (ref) 
Age (years) 
47.5 (4.08) 
 
47.83 (4.81) 47.85 (4.95) 48.17 (4.29). 
Height (cm) 163.86 (5.76) 162.5 (6.08) 162.71 (5.7) 164.19 (6.22). 
  
* = p<0.05; **= p<0.001 
 
AN = Anorexia Nervosa; BN = Bulimia Nervosa; HC = Healthy Controls; AN-R = Anorexia 
Nervosa Restricting sub-type; AN-BP = Anorexia Nervosa Binge-Purge sub-type; kg = 
kilograms; cm = centimeters; m = meters  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3: Participant characteristics (mean (SD)) in ED groups versus Healthy Controls from 
the ALSPAC FOM2 assessment   
 
 
 
Weight (kg) 
63.05 (10.51)** 59.23 (10.09)** 70.94 (18.78) 70.16 (13.51). 
 
Fat Mass (kg) 
19.77 (8.99)** 17.42 (5.5)** 25.31 (13.12) 26.1 (10.04). 
 
Lean Mass (kg) 
40.14 (3.79) 39.32 (4.14) 42.54 (6.55)* 40.93 (40.87). 
 
Current BMI (kg/m2) 
23.5 (3.87)** 22.41 (3.43)** 26.77 (6.87) 26.03 (4.85). 
 
 
N= 48 
 
N=42  
 
N=68 N=4148 
Lowest Ever BMI (kg/m2) 
EDDS Questionnaire 
16.86 (2.14)** 16.92 (2.45)** 20.52 (4.31) 20.91 (3.11). 
 
 
 
AN 
 
BN 
 
HC 
 
 
AN-R 
 
 
AN-BP 
 
    
 N= 23 N=22 N= 42 N=2012 
Age (years) 
50.99 
(3.81) 
50.75 
(3.63) 
50.12 
(4.54) 
50.98 
(4.36) 
Ref. 
  
* = p<0.05; **= p<0.001 
 
AN = Anorexia Nervosa; BN = Bulimia Nervosa; HC = Healthy Controls; AN-R = Anorexia 
Nervosa Restricting sub-type; AN-BP = Anorexia Nervosa Binge-Purge sub-type; kg = 
kilograms; cm = centimeters; m = meters 
 
 
 
 
 
 
 
 
 
 
BMD in women with ED Diagnoses  
A lifetime diagnosis of AN, but not BN, was associated with significantly lower BMD z-scores 
in crude analyses at the total body (mean difference = -0.28; 95% CI -0.49, -0.05), legs (mean 
difference = -0.28; 95% CI -0.53, -0.04), arms (mean difference =-0.31; 95% CI -0.55, -0.08) 
and hip (mean difference= -0.46; 95% CI -0.77, -0.17) (all p<0.05).  Conversely, in analyses 
adjusted for confounders, women with AN had a significantly lower BMD Z-scores for the 
total body (mean difference = -0.28; 95% CI -0.49, 0.05),  legs (mean difference = -0.28; 95% 
CI: -0.53, -0.04), and arms (mean difference = -0.31; 95% CI: -0.55, -0.08). Women with BN 
Height (cm) 
163.4 
(5.91) 
161.72 
(6.02) 
162.81 
(5.91) 
164.25 
(6.31) 
Ref. 
Weight (kg) 
61.35 
(10.28) 
* 
57.33 
(9.89) 
** 
69.11 
(18.47) 
69.78 
(12.75) 
Ref. 
Fat Mass (kg) 
19.86 
(8.46) 
** 
15.47 
7.76 
** 
23.16 
(11.16) 
* 
26.29 
(9.75) 
Ref. 
Lean Mass (kg) 
38.59 
(3.48) 
38.49 
(3.61) 
40.52 
(3.98) 
40.29 
(4.55) 
Ref. 
Current BMI (kg/m2) 
22.93 
(3.41) 
* 
21.89 
(3.35) 
** 
26.08 
(6.91) 
25.88 
(4.68) 
Ref. 
Lowest Ever BMI (kg/m2) 
EDDS Questionnaire 
N= 48 
16.86 
(2.14) 
** 
N=42 
16.92 
(2.45) 
** 
N=68 
20.52 
(4.31) 
N=4148 
20.91 
(3.11) 
Ref. 
had significantly higher total body (mean difference = 0.22; 95% CI 0.01, 0.44) and leg (mean 
difference = 0.41; 95% CI 0.18, 0.64) BA  (see Table 4 and Supplement Table 2) BMD. Finally, 
in the final model, when lowest ever BMI was included as a covariate, AN and BN were no 
longer significantly associated with BMD or BA (see Table 4 and Supplemental Table 2).  
 
In post-hoc adjusted analyses women with AN-R, but not AN-BP had lower BMD Z-scores at 
the total body (mean difference = -0.37; 95% CI -0.62, -0.12), hip (mean difference = -0.51; 
95% CI -0.82, -0.21) (Table 5), legs (mean difference = -0.42; 95% CI -0.69, -0.15) and arms 
(mean difference = 0.37; 95% CI -0.65, -0.11) when adjusted for sociodemographic variables 
and confounders.  Women with both AN-R and AN-BP showed a trend towards having a lower 
BA than women with no ED at  all anatomical sites measured.  
 
 
 
 
Table 4: Multivariate analyses from FOM1 and FOM2 Clinic. Mean Difference in Z-Scores 
between BMD and BA Measures in ALSPAC Mothers with AN or BN. 
 
 
 
 
BMD = Bone Mineral Density; BA = Bone Area; FOM1 = Focus on Mothers Clinic 1; FOM2 = Focus on 
Mothers Clinic  
Adjusted = Adjusted for Confounders including: Ethnicity, Educational Level, Height2, BA *In Analysis of BA, 
BA was excluded from the Confounding set  
 
 
 
 
 
 
FOM1 Clinic  
 
  
AN  
(59) 
 
BN  
(54) 
 
HC 
(2,942) 
 
Total Body Minus Head  ß (95% CI) p ß (95% CI) p Ref. 
Crude Analysis BMD -0.39 
(-0.67; -0.12) 
0.007 0.28 
(-0.01; 0.58) 
0.059  
 BA -0.32 
(-0.61; -0.02) 
0.025 0.09 
(-0.19; 0.36) 
0.539  
Adjusted  BMD -0.28 
(-0.49; -0.05) 
0.003 0.19 
(-0.07; 0.47) 
0.143  
 BA -0.19 
(-0.41; 0.03) 
0.087 0.22 
(0.01; 0.44) 
0.048  
Adjusted + 
Lowest Ever BMI 
BMD 0.06 
(-0.31; 0.18) 
0.627 0.19 
(-0.05; 0.42) 
0.120  
 BA 0.12 
(-0.14; 0.35) 
0.390 0.18 
(-0.05; 0.41) 
0.123  
 
FOM2 Clinic 
  
AN  
(41) 
  
BN  
(39) 
  
HC 
(1,948) 
 
Total Hip  ß (95% CI) p  ß (95% CI) p  Ref. 
Crude Analysis BMD -0.42 
(-0.69; -0.15) 
0.003 0.13 (-0.16; 0.41) 0.374  
 BA -0.29 
(-0.64; 0.05) 
0.091 -0.05 (-0.41; 0.31) 0.77  
Adjusted  BMD -0.46 
(-0.75; -0.17) 
0.002 0.07 (-0.18; 0.34) 0.449  
 BA -0.07 
(-0.37; 0.21) 
0.59 0.11 (-0.18; 0.41) 0.45  
Adjusted  
+ Lowest Ever BMI 
BMD -0.02 
(-0.36; 0.32) 
0.876 0.11 (-0.14; 0.35) 0.332  
 BA -0.04 
(-0.39; 0.31) 
0.808 0.12 (-0.18; 0.43) 0.43  
Table 5: Multiple Imputation results from FOM1 and FOM2 Clinic. Mean Difference in Z-
Scores between BMD and BA Measures in ALSPAC Mothers with lifetime AN-R or AN-BP 
diagnoses. 
 
 
FOM1 Clinic 
N=3440 
 
  
AN_R  
(N=19) 
 
AN_BP  
(N=29) 
 
HC 
(N=2,942) 
Total Body Minus Head  
 
 ß (95% CI) p ß (95% CI) p  Ref.  
Crude Analysis BMD -0.45 
(-0.79; -0.12) 
0.007 -0.24 
(-0.65; 0.18) 
0.260  
 BA -0.32 (-0.82; 0.18) 0.205 -0.27 
(-0.61; 0.05) 
0.106  
Adjusted  BMD -0.37 
(-0.62; -0.12) 
0.004 -0.13 
(-0.46; 0.19) 
0.426  
 BA -0.23 
(-0.58; 0.12) 
0.197 -0.13 
(-0.41; 0.14) 
0.333  
Adjusted + Lowest Ever BMI BMD -0.15 
(-0.42; 0.12) 
0.269 0.07 
(-0.28; 0.43) 
0.700  
 BA 0.12 
(-0.28; 0.52) 
0.560 0.15 
(-0.14; 0.45) 
0.311  
 
FOM2 Clinic 
N= 2,256 
 
  
AN_R  
(N=19) 
  
AN_BP  
(N=29) 
  
HC 
(N=1,948) 
 
Total Hip  ß (95% CI) p  ß (95% CI) p  Ref. 
Crude Analysis BMD -0.47  
(-0.76; -0.19) 
0.001 -0.35 
(-0.79; -0.08) 
0.114  
 BA -0.37  
(-0.82; 0.07) 
0.101 -0.16 
(-0.59; 0.26) 
0.450  
Adjusted  BMD -0.51  
(-0.82; -0.21) 
0.001 -0.38 
(-0.83; 0.06) 
0.093  
 BA -0.21  
(-0.54; 0.14) 
0.246 0.09 
(-0.27; 0.46) 
0.601  
Adjusted  
+ Lowest Ever BMI 
BMD -0.09  
(-0.46; 0.27) 
0.602 0.04 
(-0.42; 0.52) 
0.836  
 BA -0.03  
(-0.41; 0.34) 
0.859 0.27 
(-0.11; 0.66) 
0.165  
 
 
 
BMD = Bone Mineral Density; BA = Bone Area; FOM1 = Focus on Mothers Clinic 1; FOM2 = Focus on 
Mothers Clinic  
Adjusted = Adjusted for Confounders including: Ethnicity, Educational Level, Height2, BA *In Analysis of BA, 
BA was excluded from the Confounding set  
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BMD in women with ED Behaviours  
Lifetime Fasting was predictive of low BMD Z-scores at the legs in crude analyses (mean 
difference = -0.18; 95% CI -0.36, -0.012), and of the hip in adjusted analyses (mean difference 
= -0.21; 95% CI -0.43, -0.008). Restrictive eating was predictive of low BMD Z-scores at the 
arms (mean difference = -0.31; 95% CI -0.58, -0.03), and the hip in crude (mean difference = 
-0.34; 95% CI -0.64, -0.03) and adjusted analyses (mean difference = -0.33; 95% CI -0.63, -
0.04). When lowest ever reported BMI was included in the model neither fasting nor restrictive 
eating were significantly associated with any BMD measure. 
 
Lifetime self-induced vomiting was associated with lower BA at the total body in both crude 
(mean difference = -0.31; 95% CI -0.55, -0.08) and adjusted analyses (mean difference = -0.33; 
95% CI -0.56, -0.09), and low arm BMD Z-scores in crude analyses only (mean difference = -
0.26; 95% CI -0.49, -0.03). Misuse of medication was associated with low BMD Z-scores at 
the hip in adjusted analyses (mean difference = -0.31; 95% CI -0.58, -0.027). Similar to the 
results for fasting and restricting ED behaviours, these associations were non-significant when 
analyses additionally adjusted for lowest ever reported BMI. The associations between ED 
behaviours and total body and hip BMD and BA are presented in Table 6. 
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Table 6: Multiple Imputation Results from FOM1 and FOM2 Clinic. Mean Difference in Z-Scores between BMD and BA Measures in ALSPAC 
Mothers with lifetime ED Behaviours. 
 
 
 
BMD = Bone Mineral Density; BA = Bone Area; FOM1 = Focus on Mothers Clinic 1; FOM2 = Focus on Mothers Clinic Adjusted = Adjusted for Confounders including: 
Ethnicity, Educational Level, Height2, BA *In Analysis of BA, BA was excluded from the Confounding set  
 
FOM1 Clinic 
 
N = 3440 
  
Fasting 
(N=131) 
 
Restricting  
(N=53) 
 
Vomiting 
( N=71) 
 
Misuse of Medication 
( N=72) 
 
 
HC  
(N=2,942) 
Total Body 
 
 ß (95% CI) p ß (95% CI) p ß (95% CI) p ß (95% CI) p Ref. 
Crude Analysis BMD -0.11 
(-0.28; 0.06) 
0.211 -0.25 
(-0.52; 0.02) 
0.072 -0.15 
(-0.39; 0.08) 
0.199 -0.13 
(-0.36; 0.09) 
0.257  
 BA -0.21 
(-0.38; -0.03) 
0.021 -0.38 
(-0.65; 0.12) 
0.005 -0.31 
(-0.55; -0.08) 
0.009 -0.15 
(-0.38; 0.07) 
0.197  
Adjusted BMD -0.41 
(-0.18; 0.11) 
0.584 -0.03 
(-0.26; 0.19) 
0.774 -0.02 (0.22; 0.18) 0.852 -0.08 
(-0.27; 0.11) 
0.414  
 BA -0.12 
(-0.26; 0.02) 
0.093 -0.33 
(-0.55; -0.11) 
0.004 -0.18 
(-0.37; 0.06) 
0.059 -0.08 
(-0.27; 0.11) 
0.384  
Adjusted + Lowest 
Ever BMI 
BMD 0.02 
(-0.12; 0.17) 
0.722 0.11 
(-0.12; 0.33) 
0.362 0.04 
(-0.15; 0.24) 
0.647 -0.01 
(-0.21; 0.17) 
0.904  
 BA -0.02 
(-0.16; 0.11) 
0.733 -0.12 
(-0.34; 0.92) 
0.263 -0.08 
(-0.26; 0.09) 
0.363 0.01 
(-0.17; 0.19) 
0.884  
 
FOM2 Clinic 
N=2,256 
  
Fasting  
(N=85) 
 
Restricting  
(N=42) 
 
Vomiting  
(N=50) 
 
Misuse of Medication  
( N=49) 
 
 
HC  
(N=1,948) 
Hip 
 
 ß (95% CI) p ß (95% CI) p ß (95% CI) p ß (95% CI) p Ref. 
Crude Analysis BMD -0.18 
(-0.39; 0.03) 
0.091 -0.36 
(-0.64; -0.03) 
0.029 -0.05 
(-0.32; 0.23) 
0.748 -0.25 
(-0.54; 0.03) 
0.075  
 BA -0.11 
(-0.32; 0.11) 
0.318 0.06 
(-0.24; 0.37) 
0.668 -0.12 
(-0.39; 0.16) 
0.403 0.07 
(-0.21; 0.35) 
0.608  
Adjusted  BMD -0.22 
(-0.43; -0.001) 
0.042 -0.33 
(-0.63; -0.04) 
0.027 -0.06 
(-0.33; 0.21) 
0.668 -0.29 
(-0.58; -0.02) 
0.035  
 BA 0.05 
(-0.14; 0.23) 
0.620 0.06 
(-0.21; 0.32) 
0.650 0.03 
(-0.22; 0.27) 
0.832 0.13 
(-0.11; 0.38) 
0.271  
Adjusted + Lowest 
Ever BMI 
BMD -0.11 
(-0.31; 0.09) 
0.299 -0.08 
(-0.36; 0.21) 
0.606 0.11 
(-0.16; 0.36) 
0.437 -0.18 
(-0.45; 0.08) 
0.191  
 BA 0.11 
(-0.08; 0.029) 
0.280 0.19 
(-0.08; 0.45) 
0.160 0.11 
(-0.13; 0.35) 
0.385 0.21 
(-0.04; 0.45) 
0.106  
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Post-hoc analyses investigating ED behaviours as mutually exclusive categories revealed that 
when women with vomiting or misuse of medication were excluded from the analyses  fasting, 
but not restrictive eating, was associated with a significantly low BMD at the arms (mean 
difference =-0.25; 95% CI: -0.49, -0.01) in adjusted analyses.  Restrictive eating remained 
predictive of a low BA, specifically at total body BA (mean difference =-0.32; 95% CI: -0.64, 
-0.02). Analyses only including women who exclusively either vomited of misused medication 
(or engaged in both), showed that neither of these beahviours were predictive of poor bone 
health in isolation. 
 
Discussion 
 
 
This study found that a lifetime diagnosis of AN, but not BN was associated with low BMD at 
all sites measured, including total body, the hip, the arms and the legs. When separated post-
hoc, AN-R, rather than AN-BP was individually predictive of low total body, hip, arms, and 
legs BMD. The association between AN, and specifically AN-R,  and BMD and BA at all 
skeletal sites diminished however, when lowest ever BMI was included in the regression 
model, with the mean difference decreasing by 4-5 fold. ED behaviours including fasting and 
restricting were individually predictive of poor bone health outcomes at both total body and 
the hip, with mean differences in BMD similar to those observed between AN-R and healthy 
women. Vomiting and misuse of medication when studied in isolation, were not significantly 
associated with either bone health outcomes in this study. As with ED diagnoses, these 
associations significantly decreased when lowest ever BMI was included in the regression 
model, with a greatly reduced effect size and wider confidence intervals. 
 
This study supports evidence that AN but not BN is prospectively associated with low BMD 
and BA [18, 20, 30], and that this association is mostly driven by  restricting (AN-R), rather 
than binge-purging (AN-BP) AN subtypes. Previous research has found that women with BN 
have significantly lower BMD at the total body and the spine [12, 21, 31] than healthy women 
regardless of BMI. A recent meta-analysis by our group found that women with BN had lower 
BMD at the spine (SMD -0.47) than healthy control women, indicating an increased fracture 
risk of between 30 and 50% [12]. However, when separating those with and without a history 
of AN in post-hoc analyses, it was evident that only women with BN and a history of AN 
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presented with significantly low BMD [18-20], suggesting that a diagnosis of BN alone may 
not be a risk factor for poor bone health in adulthood. 
 
Fasting and restricting ED behaviours were associated with low  total body and hip BMD and 
BA; with the mean difference approximately halving in the majority of these analyses when 
including lowest ever BMI in the model. Fasting for prolonged periods of time and restricting 
food intake are associated with poor nutritional intake [32], with calcium, vitamin D and 
vitamin K all known to contribute to bone accrual and the maintenance of BMD [33-35]. 
Furthermore, endocrine changes, including disruption of the HPG-axis resulting in deficiency 
of the sex hormones, oestrogen and testosterone, have been suggested to contribute to loss of 
BMD in AN [6, 36, 37]. Reaching a significantly low body weight in one’s lifetime, as is 
evident in those who report fasting and restricting ED behaviours, is likely to be closely linked 
to both malnutrition and also the disruption of endocrine factors known to be associated with 
bone health. This supports previous research which suggests that a significantly low BMI is an 
independent risk factor for poor bone health outcomes [16, 38] 
 
Vomiting and misuse of medication at any time throughout lifetime were found to be predictive 
of poor bone health outcomes in this study when present alongside either fasting or restricting 
behaviours. These ED behaviours are characteristic of BN, AN-BP and also sub-EDs in DSM-
5 diagnostic categories [39]. However, this study found that vomiting and misuse of medication 
ED behaviours were not individually predictive of poor bone health outcomes, suggesting that 
fasting and restricting (AN-R ‘type’ behaviours) are driving the relationship between EDs and 
low BMD.  
 
This study found that the associations between ED diagnoses and ED behaviours and bone 
health outcomes diminished when the lowest ever reported BMI was included in the model, 
indicating that having a low BMI explains to a great extent the poor bone health outcomes in 
women with ED. Of note, the mean BMI of all ED diagnosis and behaviour groups was >22.5 
kg/m2 at the time of a DXA scan, with only 5 women diagnosed with AN at any time during 
life remaining clinically underweight (BMI < 18.5 kg/m2). It is thus evident that weight gain 
in the AN group was not sufficient to fully recover BMD, as reported in previous research [16, 
33, 40, 41].  Previous studies investigating endocrine mediators of the relationship between 
AN and poor bone health have reported that a low BMI is a significant predictor of both 
endocrine disruption and loss of BMD [7, 42]. Similarly, this study found that the lowest ever 
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reported BMI explained a large proportion of variance in all analyses presented here. Our 
findings support previous reports of low BMI being an independent risk factor for poor bone 
health outcomes [16, 43]. 
 
Although BMD is known to be a key predictor of fracture risk in both children and adults, BA 
is an indicator of skeletal size and so is particularly relevant when considering those with EDs 
who may have a small skeleton as well as a low body weight. There was a trend towards a low 
BA in those with AN (AN-R and AN-BP), and also in those reporting fasting, restricting and 
vomiting ED behaviours. However, all groups showed larger effect sizes in the analyses of 
BMD, indicating that these EDs and ED behaviours have a greater effect on BMD than BA at 
all skeletal sites.  
 
Our findings have to be understood in light of strengths and limitations. The prospective nature 
of this study allowed us to investigate ED at any time during life and their association with 
bone health outcomes in mid-life. Furthermore, this is the first study to investigate the 
association between ED behaviours and bone health outcomes in order to determine which ED 
behaviours within broader ED phenotypes might affect bone health. Whereas the majority of 
previoius studies in this field have focused on clinical samples, the use of a population-based 
sample using a longitudinal study design allows us to widen what we know about the effect of 
ED on bone health to women who do not necessarily access healthcare for their ED, and also 
to determine if women with less severe forms of ED are also at risk for poor bone health 
outcomes.  
 
Although the sample used in this study is large, there are a number of limitations that need to 
be taken into account. Two ALSPAC study clinics were used in this study, which were 
conducted at separate time-points. Women in this study thus received a hip DXA scan (FOM2 
clinic) on average two years later than the total body DXA scan (FOM1 clinic) [44]. As only 
pre- or peri-menopausal women who attended the FOM1 clinic were invited to attend FOM2, 
the findings from the FOM2 clinic (hip bone health measures) are prone to selection bias and 
thus only generalizable to other pre- or peri-menopausal women.  
 
Participation in the ED substudy was biased towards women with a higher level of education, 
and those with fewer children, who were more likely to participate [25]. Furthermore, the 
nature of the ALSPAC study recruitment results in the entirety of our sample being mothers of 
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one or more children. Pregnancy and parity are both known to have an effect on bone health 
outcomes [45-48]. Women with AN in this study may have either a higher BMI or less severe 
symptoms than women with AN who fail to become pregnant, as women with acute AN may 
take longer to become pregnant or have difficulty conceiving in comparison to healthy women 
[49, 50]. Furthermore, attrition was negatively predicted by the presence of ED behaviours and 
diagnoses, with these women being less likely to drop out of the study. Hence, it is possible 
that the relationship between ED diagnoses and ED behaviours and BMD is exaggerated in this 
study due to this slightly skewed sample.  
Conclusions 
 
For the first time, we show that lifetime ED behaviours (fasting and restrictive eating) as well 
as AN-R are associated with low BMD in mid-life adult women across four anatomical sites. 
As poor bone health was common among this sample of ED women, this study has important 
public health as well as clinical implications for early identification of osteopenia and 
osteoporosis, before the occurrence of fractures.    
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Supplemental Tables  
 
Supplemental Table 1: Comparison of socio-demographic data of the ALSPAC cohort and 
the sample included in the current study 
 
 
Whole ALSPAC Sample 
(N=12,957) 
Sample available for 
Analysis (N=5,181) 
Chi-square (df, N), p value 
Ethnicity (white) n, (%) 12,111 (97.21%) 5,144 (97.65%) 6.49 (1, 12459), p =0.011 
Parity (multiparous) n, (%)    7,144 (55.14%) 2,717 (52.4%) 151.39 (1, 7216), p < 0.001 
Education (A Level +) n, (%) 3,390 (46.98%) 2,374 (52.57%) 25.34 (1, 12957), p < 0.001 
 
ALSPAC = Avon Longitudinal Study of Parents and Children 
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Supplemetal Table 2: Multivariate analyses from FOM1 assessment: mean  
Difference in Z-Scores between Leg and Arm BMD and BA Measures in ALSPAC Mothers 
with AN or BN diagnoses ever. 
 
 
 
 
 
BMD = Bone Mineral Density; BA = Bone Area; FOM1 = Focus on Mothers Clinic 1;  
Adjusted = Adjusted for Confounders including: Ethnicity, Educational Level, Height2, BA *In Analysis of BA, 
BA was excluded from the Confounding set  
 
 
FOM1 
  
AN  
(59) 
   
BN 
(54) 
 
HC 
(2,942) 
 
Legs  ß (95% CI) p ß (95% CI) p Ref. 
Crude Analysis BMD -0.37 (0.66; -
0.09) 
0.009 0.19 (0.09; 
0.47) 
0.176  
 BA -0.17 (-0.43; 
0.09) 
0.190 0.25 (-0.4; 
0.54) 
0.090  
Adjusted  BMD -0.28 (-0.53; -
0.04) 
0.023 0.13 (-0.12; 
0.38) 
0.314  
 BA -0.01 (-0.17; 
0.14) 
0.921 0.41 (0.18; 
0.64) 
0.001  
Adjusted + 
Lowest Ever 
BMI 
BMD -0.05 (-0.32; 
0.22) 
0.718 0.12 (-0.12; 
0.35) 
0.331  
 BA  0.27 (0.08; 
0.45) 
0.004 0.37 (0.16; 
0.59) 
0.001  
Arms 
 
 ß 
(95% CI) 
p ß 
(95% CI) 
p Ref. 
Crude Analysis BMD -0.39 (-0.65; 
0.14) 
0.003 -0.01 (-0.28; 
0.26) 
0.943  
 BA -0.08 (-0.41; 
0.23) 
0.590 0.05 (-0.35; 
0.46) 
0.777  
Adjusted  BMD -0.31 (-0.55; -
0.08) 
0.010 -0.09 (-0.34; 
0.14) 
0.430  
 BA 0.05 (-0.19; 
0.28) 
0.705 0.19 (-0.17; 
0.56) 
0.288  
Adjusted + 
Lowest Ever 
BMI 
BMD -0.16 (-0.43; 
0.11) 
0.227 -0.12 (-0.34; 
0.13) 
0.385  
Crude Analysis BA 0.06 (-0.19; 
0.32) 
0.630 0.19 (-0.16; 
0.55) 
0.286  
